Tissue-specific cytochrome c oxidase assembly defects due to mutations in \( \text{SCO2} \) and \( \text{SURF1} \)

Lukas STIBUREK*, Katerina VESELA*, Hana HANSIKOVA*, Petr PECINA†, Marketa TESAROVA*, Leona CERNA*, Josef HOUSTEK† and Jiri ZEMAN†.

†Department of Pediatrics and Center of Applied Genomics, 1st Faculty of Medicine, Charles University, Ke Karlovu 2, 128 08 Prague, Czech Republic, and †Department of Bioenergetics, Institute of Physiology, Academy of Sciences of the Czech Republic, 142 20 Prague, Czech Republic

The biogenesis of eukaryotic COX (cytochrome c oxidase) requires several accessory proteins in addition to structural subunits and prosthetic groups. We have analysed the assembly state of COX and SCO2 protein levels in various tissues of six patients with mutations in \( \text{SCO2} \) and \( \text{SURF1} \). SCO2 is a copper-binding protein presumably involved in formation of the Cu\( _{a} \) centre of the COX2 subunit. The function of SURF1 is unknown. Immunoblot analysis of native gels demonstrated that COX holoenzyme is reduced to 10–20\% in skeletal muscle and brain of \( \text{SCO2} \) and \( \text{SURF1} \) patients and to 10–30\% in heart of \( \text{SCO2} \) patients, whereas liver of \( \text{SCO2} \) patients contained normal holoenzyme levels. The steady-state levels of mutant SCO2 protein ranged from 0 to 20\% in different \( \text{SCO2} \) patient tissues. In addition, eight distinct COX subcomplexes and unassembled subunits were found, some of them identical with known assembly intermediates of the human enzyme. Heart, brain and skeletal muscle of \( \text{SCO2} \) patients contained accumulated levels of the COX1·COX4·COX5A subcomplex, three COX1-containing subcomplexes, a COX4·COX5A subcomplex and two subcomplexes composed of only COX4 or COX5A. The accumulation of COX1·COX4·COX5A subcomplex, along with the virtual absence of free COX2, suggests that the lack of the Cu\( _{a} \) centre may result in decreased stability of COX2. The appearance of COX4·COX5A subcomplex indicates that association of these nucleus-encoded subunits probably precedes their addition to COX1 during the assembly process. Finally, the consequences of \( \text{SCO2} \) and \( \text{SURF1} \) mutations suggest the existence of tissue-specific functional differences of these proteins that may serve different tissue-specific requirements for the regulation of COX biogenesis.

Key words: assembly pathway, Cu\( _{a} \) centre, cytochrome c oxidase, mitochondria, \( \text{SCO2} \), \( \text{SURF1} \).

INTRODUCTION

Eukaryotic COX (cytochrome c oxidase), the terminal enzyme of the mitochondrial respiratory chain, is embedded in the inner mitochondrial membrane where it catalyses the transfer of electrons from reduced cytochrome c to molecular oxygen and further couples this reaction with proton translocation across the inner membrane. Mammalian COX is a multisubunit complex of approx. 200 kDa composed of 13 subunits encoded by both the mitochondrial and nuclear genes. The mitochondrial encoded subunits COX1, COX2 and COX3 are evolutionarily conserved and form the catalytic and structural core of the enzyme [1]. The remaining ten evolutionarily younger subunits are encoded by the nuclear genome and are associated with the surface of the complex core. These small polypeptides are required for the stability and assembly of the holoenzyme and are also involved in modulation of its activity in response to various cellular stimuli [2]. Tissue-specific isoforms of subunits COX4, COX6A, COX6B and COX7A were identified in humans [3,4]. In addition to the constituent protein subunits, COX contains several redox-active prosthetic groups directly involved in electron transfer. These are two haem A moieties (\( a \) and \( a' \)) and two copper centres (Cu\( _{a} \) and Cu\( _{b} \)). The Cu\( _{a} \) centre and both haem A moieties are located within the hydrophobic interior of COX1 subunit comprised of 12 transmembrane \( \alpha \)-helices. The binuclear Cu\( _{b} \) centre is located within the ten-stranded \( \beta \)-barrel that forms the polar C-terminal domain of COX2, which protrudes into the intermembrane space. This subunit is anchored to the membrane by two N-terminal transmembrane \( \alpha \)-helices that make extensive contacts with COX1 [5]. The assembly pathway of mammalian COX in the inner mitochondrial membrane is a sequential and relatively slow process that is still not fully understood [6,7]. Studies on yeast have identified more than 30 accessory proteins essential for proper biosynthesis or assembly of the enzyme. To date, mutations in six nucleus-encoded factors (SURF1, COX1, COX2, COX10, COX15 and LRPPRC) required for the assembly of the COX complex have been identified in humans [6–8].

SCO2 is an inner mitochondrial membrane copper-binding protein presumably involved in copper transfer to the Cu\( _{a} \) centre of COX2. The molecular mass of its fully processed form is approx. 25 kDa. Mutations in human \( \text{SCO2} \) cause fatal infantile COX deficiency with the predominant symptoms being encephalopathy and hypertrophic cardiomyopathy. To date, all patients identified were either compound heterozygotes for 1541G \( > \) A (where 1541G \( > \) A denotes the guanine \( > \) adenine nucleotide transition at the position 1541 of the DNA) mutation, with the other allele carrying either a nonsense or missense mutation, or homozygotes for this common 1541G \( > \) A transition, predicting a E140K amino acid substitution near the highly conserved CXXXC putative copper-binding motif [9–11]. The most severe cases (early onset) are compound heterozygotes, while patients homozygous for E140K substitution have a comparatively milder phenotype (delayed onset, less progressive).

Human SURF1 is a 30 kDa transmembrane protein localized in the inner mitochondrial membrane [12,13]. The precise function of this protein is still unknown, but recently it was suggested that...

Abbreviations used: BN-PAGE, Blue Native PAGE; COX, cytochrome c oxidase; CS, citrate synthase; DDM, n-dodecyl-\( \beta \)-D-maltoside; SDH, succinate:ubiquinone oxidoreductase; VDAC, voltage-dependent anion channel.

To whom correspondence should be addressed (email jzem@lf1.cuni.cz).
human SURF1 promotes the association of COX2 with the COX assembly intermediate composed of COX1, COX4 and COX5A [14], which was originally described as COX1- and COX4-containing assembly intermediate S2 [15]. Mutations in human SURF1 cause Leigh syndrome, a fatal neurological disorder associated with severe isolated COX deficiency and characterized mainly by bilaterally symmetrical necrotic lesions in the basal ganglia and brainstem [16,17]. Nearly all reported SURF1 patients carried loss-of-function mutations that predict either truncated and unstable protein product or unstable mRNA [18].

Histochromalyses and enzyme activity measurements show that SCO2 mutations result in a tissue-specific decrease of COX activity, with heart and skeletal muscle being most severely affected. In contrast, cultured fibroblasts and liver were shown to retain high residual activity [9–11], indicating tissue-specific differences in COX biogenesis or maintenance. The COX activity was reduced to approx. 10% of control values in SURF1 patient fibroblasts [14], and the skeletal muscle of SURF1 patients was repeatedly shown to retain approx. 20% of residual COX activity [19]. In SURF1 fibroblasts, the reduction of COX activity was shown to be accompanied by a similar decrease in holoenzyme levels and also by a marked accumulation of COX subcomplexes, suggesting that the residual enzyme is fully active and that the enzyme deficiency stems from impaired assembly or maintenance of the protein complex [14].

The aim of the present study was to examine and compare the consequences of SCO2 and SURF1 mutations in various human tissues. We have investigated the steady-state levels of COX holoenzyme and the presence and composition of COX subcomplexes in tissues and primary fibroblast cultures from three patients harbouring SURF1 mutations and from three patients carrying mutations in SURF1. We directly demonstrate that mutations in both SURF1 and age-related controls. Primary skin fibroblast cultures were established from forearm skin biopsies. Open muscle biopsies were obtained from the tibialis anterior muscle and were frozen at −80°C. Post-mortem heart, liver, brain (basal ganglia) and kidney tissue specimens were removed and frozen less than 2 h after death.

**Isolation of mitoplasts and mitochondria**

Skeletal muscle, brain and kidney mitochondria were isolated according to standard differential centrifugation procedures [23] in a buffer comprising 150 mM KCl, 10 mM Tris/HCl, 2 mM EDTA and 2 µg/ml aprotinin (pH 7.4) at 4°C. Heart and liver mitochondria were isolated in a buffer comprising 250 mM sucrose, 20 mM Tris/HCl, 2 mM EDTA and 2 µg/ml aprotinin (pH 7.4) at 4°C. Mitoplast-enriched fractions were prepared from cultured fibroblasts using digitonin (Sigma–Aldrich) as described in [24], with a final digitonin/protein ratio of 0.6 mg/mg. Protein concentrations were determined with the Bio-Rad Protein Assay kit (Bio-Rad Laboratories). All samples were stored at −80°C.

**Enzyme activity assays**

Activities of COX and CS (citrate synthase) were measured spectrophotometrically in fibroblasts and isolated tissue mitochondria essentially as described in [25].

**Electrophoresis**

BN-PAGE (Blue Native PAGE) [26] was used for separation of mitochondrial membrane protein complexes on polyacrylamide 8–15, 8–16 and 10–18% (w/v) gradient gels using a Mini Protean® 3 System (Bio-Rad Laboratories). Mitoplasts or mitochondria were solubilized with DDM (n-dodecyl β-D-maltoside; Sigma–Aldrich) with a final DDM/protein ratio of 1.0 mg/ml in a buffer containing 1.5 M aminocaproic acid, 2 mM EDTA and 50 mM Bis-Tris (pH 7.0) at 4°C. Serva Blue G (Serva) was added to solubilized protein at a concentration of 0.1 mg/ml of detergent, and 5–50 µg of protein was loaded for each lane. The electrophoresis was performed at 40 V, 4°C for 1 h and then at 100 V, 4°C. Tricine SDS/PAGE was carried out under standard conditions with 12% polyacrylamide, 0.1% (w/v) SDS and 5.5 M urea gels. Mitochondrial fractions were dissociated in 50 mM Tris/HCl (pH 6.8), 12% (v/v) glycerol, 4% SDS, 2% (v/v) 2-mercaptoethanol and 0.01% (w/v) Bromophenol Blue for 30 min at 37°C, and approx. 10 µg of protein was loaded for each lane. For two-dimensional BN/SDS/PAGE [26], strips of the
first-dimension gels were incubated for 40 min in 1% 2-mercaptoethanol and 1% SDS and then for 10 min in 1% SDS, and denatured proteins were then resolved in the second dimension on 13% polyacrylamide, 0.1% SDS and 5.5 M urea gels [14,26].

**Preparation of a polyclonal antibody raised against human SCO2**

An SCO2-specific antibody was generated by injecting rabbits with a synthetic peptide specific for the C-terminal part of human SCO2 (CGRSRSAEQISDSVRRHMAAF). Testing of the specificity of the SCO2 antiserum revealed that affinity purification was not required, and crude serum was used in all subsequent experiments.

**Immunoblot analysis**

Proteins were electroblotted from the gels on to Immobilon™-P PVDF membranes (Millipore) using semi-dry transfer for 2 h at a constant current of 0.8 mA/cm². Membranes were air-dried overnight, rinsed twice with 100% (v/v) methanol and blocked in PBS and 10% (w/v) non-fat dried milk for 1 h. Primary detection was performed with mouse monoclonal antibodies raised against COX subunits COX1 (A-6403; 1 μg/ml), COX2 (A-6404; 1 μg/ml), COX4 (A-21348; 2 μg/ml), COX5A (A-21363; 2 μg/ml) and COX6B (A-21366; 1 μg/ml) (Molecular Probes), with rabbit polyclonal antiserum raised against human SCO2 (1:1000) and with monoclonal antibodies raised against the flavoprotein subunit of SDH (succinate:ubiquinone oxidoreductase) (A-11142; 0.1 μg/ml) (Molecular Probes) and the VDAC (voltage-dependent anion channel) (31HL Ab-1; 1.4 μg/ml) (Calbiochem) at indicated dilutions. Blots were incubated with primary antibodies in PBS, 0.3% (v/v) Tween 20 and 1% non-fat dried milk for 2 h. Secondary detection was carried out with goat anti-mouse IgG–horseradish peroxidase conjugate (A9824; 1:1000) (Sigma–Aldrich) or with goat anti-rabbit IgG–horseradish peroxidase conjugate (A0545; 1:2000) (Sigma–Aldrich) in PBS, 0.1% Tween 20 and 1% non-fat dried milk for 1 h. The blots were developed with West Pico Chemiluminescent substrate (Pierce) and exposed to Kodak BioMax Light films (Kodak). The films were subsequently scanned and digital images were analysed using the Quantity One application (Bio-Rad Laboratories).

**RESULTS**

**Activities of COX in SCO2 and SURF1 patient tissues**

Previous respiratory chain enzyme activity measurements of tissues and cell cultures from our patients with SCO2 and SURF1 mutations showed an isolated tissue-specific COX deficiency in all patients [20–22]. To determine the residual COX activity of the mitochondrial preparations used in the present study, we expressed COX activity relative to the activity of the mitochondrial marker enzyme, CS. Severe isolated defects of COX activity were found in the SCO2 patient heart, skeletal muscle and brain, whereas in fibroblasts and liver the activity was only moderately affected (Table 1). In contrast, severe reduction of COX activity was found in all of our SURF1 fibroblast cultures (Table 1).

**Steady-state levels of COX holoenzyme in SCO2 and SURF1 patient tissues**

All mitochondrial preparations used in the present study were balanced on the basis of the immunoblot signal of the mitochondrial inner membrane protein complex SDH. To determine the residual steady-state levels of COX holoenzyme in tissues of patients as a percentage of control values, dilutions of control mitochondria were loaded on the same gels. Mitochondrial samples were resolved using BN-PAGE and subsequently probed with an anti-COX1 antibody. In heart mitochondria from patients P1, P2, P3 and P4, the steady-state levels of COX holoenzyme were found to be approx. 25, 30, 10 and 40% of control values respectively (Figures 1A and 1B). Mitochondria from basal ganglia of patients P1–P3 and P4 contained approx. 20 and 15% of residual holoenzyme respectively (Figure 1C). In skeletal muscle from patients P1, P2, P5 and P6, the holoenzyme levels were approx. 10, 20, 15 and 10% of control values respectively (Figure 1D). In primary fibroblasts, the steady-state levels of COX holoenzyme were found to be approx. 70% of control values in the case of patients P1 and P2, approx. 60% in the case of patient P3 (Figure 1E) and approx. 15% in the case of patients P5 and P6 (Table 1). The liver samples of SCO2 patients (P1–P3) were the least affected and contained similar steady-state levels of COX holoenzyme to control samples, whereas in SURF1 patient liver (P4) the holoenzyme was found to be approx. 80% of control values (Figure 1F) (Table 1).

**Subcomplexes of COX in SCO2 and SURF1 patient tissues**

Mitochondrial preparations from various SCO2 and SURF1 patient tissues, primary fibroblast cultures and control samples were resolved using either BN-PAGE or two-dimensional BN/SDS/PAGE and subsequently probed with anti-COX subunit-specific monoclonal antibodies in order to detect the presence and possible accumulation of COX subcomplexes and to uncover their subunit composition. In addition to holoenzyme complex (Figures 1A and 3A, complex a), heart samples of SCO2 patients contained

---

**Table 1** Comparison of relative protein content of COX holoenzyme with relative COX activity in various tissues of SCO2 patients P1–P3 and SURF1 patients P4–P6

<table>
<thead>
<tr>
<th>Tissue</th>
<th>COX/SDH content (%)</th>
<th>COX/CS activity (%)</th>
<th>COX/SDH content (%)</th>
<th>COX/CS activity (%)</th>
<th>COX/SDH content (%)</th>
<th>COX/CS activity (%)</th>
<th>COX/SDH content (%)</th>
<th>COX/CS activity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart</td>
<td>25</td>
<td>8</td>
<td>30</td>
<td>34</td>
<td>10</td>
<td>30</td>
<td>40</td>
<td>n.d.</td>
</tr>
<tr>
<td>Muscle</td>
<td>10</td>
<td>19</td>
<td>20</td>
<td>28</td>
<td>n.d.</td>
<td>21</td>
<td>n.d.</td>
<td>11</td>
</tr>
<tr>
<td>Brain</td>
<td>20</td>
<td>16</td>
<td>20</td>
<td>18</td>
<td>20</td>
<td>13</td>
<td>n.d.</td>
<td>15</td>
</tr>
<tr>
<td>Liver</td>
<td>100</td>
<td>76</td>
<td>100</td>
<td>64</td>
<td>100</td>
<td>100</td>
<td>80</td>
<td>n.d.</td>
</tr>
<tr>
<td>Fibroblasts</td>
<td>70</td>
<td>62</td>
<td>70</td>
<td>82</td>
<td>60</td>
<td>100</td>
<td>10</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Protein content of COX holoenzyme normalized to protein content of SDH is expressed as a percentage of control values (COX/SDH content). Values of COX activity normalized to CS activity are expressed as a percentage of the mean reference range (COX/CS activity). n.d., not determined.
eight distinct COX subcomplexes (b–i). Prolonged exposure of the blots revealed the presence of six of them (b–f and i) also in control heart samples (Figures 2B and 3A). Subcomplexes c–i were found in SCO2 heart samples at highly accumulated levels, whereas only subcomplexes b and f were found slightly increased in the heart of the SURF1 patient (Figure 1A). Mitochondria from SCO2 skeletal muscle contained increased levels of seven distinct subcomplexes (Figure 3C, c–i), apparently identical with that found in SCO2 patient heart (Figure 1A). Mitochondria from SURF1 patient kidney contained moderately increased subcomplexes with migration similar to subcomplexes c–f and i from SCO2 patient heart (Figure 3D). We did not detect any conclusive accumulation of COX subcomplexes in SCO2 patient fibroblasts (Figures 1E and 3E).

Steady-state levels of SCO2 protein in various tissues of SCO2 patients

Mitochondrial fractions and fibroblast lysates were resolved using SDS/PAGE and subsequently probed with polyclonal antiserum raised against human SCO2. Equal loading was verified with an antibody raised against the mitochondrial outer membrane protein VDAC. The SCO2 protein was undetectable in all SCO2 brain samples and in heart of patients P2 and P3 (Figure 4). In heart of patient P1 and liver of patients P1 and P3, the levels of mutant SCO2 were approx. 5% of control values. In fibroblasts of patients P1–P3, the residual SCO2 was approx. 20% of control values, while in liver of patient P2 it was approx. 10% of control values (Figure 4).
Mitochondrial fractions (10–50 µg) from various tissues of SCO2 patient P1 and control samples were resolved using two-dimensional BN/SDS/PAGE, electroblotted on to PVDF membranes and probed simultaneously with monoclonal antibodies specific for subunits COX1, COX2, COX4 and COX5A. Sample loads and exposures of films to the blots were chosen such that the signals corresponding to holoenzyme complex a were of similar intensities within both control and patient immunoblots. Immunoreactive material was visualized by chemiluminescence. The positions of COX holoenzyme (a) and COX subcomplexes (b–i) and the migration of molecular-mass standards (kDa) are indicated.

**DISCUSSION**

The present study represents the first investigation of the assembly state of COX in various clinically affected tissues from patients with SCO2 and SURF1 mutations. Although both SCO2 and SURF1 proteins are thought to act at a similar stage of COX assembly, patients carrying mutations in respective genes present with distinct clinical phenotypes [9–11,16–19]. Quantitative immunoblot analysis of native gels revealed tissue-specific COX assembly defects in all patients studied that corresponded to the enzyme activity measurements. The steady-state levels of mutant SCO2 protein were found severely reduced in all the probed SCO2 patient tissues. The subunit composition of COX subcomplexes identified demonstrates the involvement of human SCO2 protein in biogenesis or maintenance of COX2 and suggests an addition to the current model of the COX assembly pathway.

In our previous work, we have determined the COX activity in several tissues from six patients with mutations in SCO2 [20] that revealed the COX defect to be most pronounced in heart, brain and muscle, moderate or low in liver, and very low or undetectable in fibroblasts. In this study, we present a detailed proteomic analysis of three of these cases in order to reveal how the SCO2 genetic defect manifests at the level of COX biosynthesis and assembly in different tissues.

The COX holoenzyme was repeatedly shown to be reduced to approx. 15 % in SURF1 patient fibroblasts, including our patients P4–P6 [12,14,22,27]. Although skeletal-muscle samples of our SURF1 patients revealed a similar decrease in COX holoenzyme to cultured fibroblasts, SURF1-deficient heart and liver contained substantially higher levels of residual holoenzyme. In contrast, the tissue-specific consequences of SCO2 mutations, mainly the profound difference between the residual COX activity in skeletal muscle and fibroblasts, have previously been reported [9,20]. Recently, it was shown that COX holoenzyme is only moderately decreased in immortalized SCO2 patient fibroblasts [28]. In the present study, we show that despite very low levels of mutant protein, the livers of SCO2 patients display practically no reduction of fully assembled COX, corresponding to high residual activity. In our previous study, we have found more pronounced decrease in COX activity (39 % of COX/CS) in liver homogenate of an additional SCO2 E140K homozygote patient [20], but due to the lack of material we could not examine the COX assembly state and enzyme content in this case. In contrast, liver and fibroblasts with mutations in SCO1, the paralogous gene of SCO2, were reported with severe reduction of COX activity and holoenzyme content respectively [14,29]. The recombinant human E140K SCO2 protein was shown to have a diminished copper-binding capacity and an altered conformational state [30]. Consistent with the latter finding, our results demonstrate that E140K mutation leads to lowered stability of SCO2 protein, as its levels are drastically decreased in mitochondria of patients. The SCO2 E140K homozygotes present with delayed onset of hypertrophic cardiomyopathy when compared with compound heterozygotes [20,31]. In line with this, heart samples from our E140K homozygote patient fibroblasts revealed a substantially milder assembly impairment than that from the E140K/Q53X compound heterozygote. However, we did not detect any substantial difference in the amount of residual SCO2 between the heterozygote and both homozygotes.

In addition to reduced holoenzyme, patient tissues contained varying levels of COX subcomplexes and unassembled subunits.

**Figure 4 Steady-state levels of SCO2 protein in heart, brain, liver and fibroblasts of SCO2 patients**

Mitochondrial fractions from heart (A), brain (B) and liver (C) samples (~10 µg) of SCO2 patients (P1–P3) and whole cell lysates (~10 µg) of SCO2 patient fibroblasts (D) were resolved using SDS/PAGE (12 % polyacrylamide), electroblotted on to PVDF membranes and probed with polyclonal antiserum raised against human SCO2 or with monoclonal antibody raised against the mitochondrial outer membrane protein VDAC. Two aliquots of control mitochondria corresponding to indicated dilutions of control samples were loaded on the same gels. Immunoreactive material was visualized by chemiluminescence.
Fibroblasts with mutations in \textit{SURF1} were repeatedly shown with increased levels of COX assembly intermediates S1 and S2 \cite{12,14,27}, and \textit{SCO}1 fibroblasts were shown to accumulate subcomplexes comprising COX1 and COX4 \cite{14}. We have identified eight distinct COX subcomplexes (b–i) in various tissues of our \textit{SCO}2 and \textit{SURF1} patients. In addition to monomeric holoenzyme complex (a), all samples contained subcomplex b of approx. 180 kDa that corresponds to the previously identified assembly intermediate S3, which, except for COX6A and either COX7A or COX7B, contains all COX subunits \cite{15}. Heart, skeletal muscle and brain of \textit{SCO}2 patients contained highly increased levels of a 110 kDa subcomplex c composed of COX1, COX4 and COX5A, very likely identical with the assembly intermediate S2 \cite{15} and with COX1·COX4·COX5A sub-assembly from \textit{SURF1} fibroblasts \cite{14}. In addition, \textit{SCO}2 heart, skeletal muscle and brain contained increased levels of subcomplexes d–f of 60–90 kDa. They involved solely COX1 subunit and might be identical with subassemblies d–f from \textit{SURF1} patient fibroblasts \cite{14}. We assume that subcomplex f represents unassembled COX1 subunit and might thus correspond to assembly intermediate S1 \cite{15}. In \textit{SCO}2 brain mitochondria, subcomplex c was detectable almost exclusively with anti-COX1 antibody, and the ratio of subcomplexes d–f to subcomplex c was substantially lower here when compared with \textit{SCO}2 heart and skeletal muscle. This might reflect more efficient clearance of partially assembled COX subunits in brain mitochondria. This is further supported by the fact that, in contrast with heart and skeletal muscle, control brain mitochondria did not reveal, even after very sensitive detection, any COX subcomplexes, except for very low levels of ubiquitous subcomplex b (results not shown). Interestingly, only subcomplexes b and f were found slightly accumulated in the heart of our \textit{SURF1} patient, although fibroblasts from this patient contained highly increased levels of four subcomplexes comprising COX1, COX4 and COX5A \cite{14}. Furthermore, despite severe reduction of holoenzyme, the brain sample from the identical patient did not contain any accumulated COX subcomplexes, and also \textit{SURF1} skeletal-muscle samples showed rather faint accumulation of subcomplexes, pointing to another tissue-specific aspect of \textit{SURF1} deficiency.

In the absence of one or more mitochondrially encoded subunits, the levels of COX4 and COX5A are the least affected \cite{32–39}. Both subunits were also shown to be closely positioned within the X-ray structure of the bovine enzyme \cite{5}. Therefore it was suggested that they might already be associated before assembly with COX1 \cite{40}. Apparently, the COX4·COX5A subcomplex of approx. 40 kDa (g) from \textit{SCO}2 patient samples represents the proposed heterodimer. According to the current model of the COX assembly pathway, the association of subunits starts with the interaction of COX1 with either COX4 or COX5A \cite{14,15,40}. Instead, our results demonstrate that the mutual association of these nucleus-encoded subunits probably precedes their addition to COX1 during the assembly process (Scheme 1).

It was previously shown that pools of unassembled COX subunits exist \cite{41}. In fact, subcomplexes h and i with a molecular mass of approx. 10–20 kDa are composed of single COX4 and COX5A subunits respectively and very likely represent unassembled subunits. This indicates that high residual levels of these subunits reported from \textit{SCO}2 patient tissues \cite{9,11,42} and from cells devoid of one or more mitochondrially encoded subunits \cite{33–40} are attributable to (i) high intrinsic stability of both subunits and (ii) their association with each other and COX1. The lower levels of unassembled COX4, compared with COX5A, observed in most of the probed tissues, very likely reflect the lower intrinsic stability of the COX4 polypeptide. This is further supported by the appearance of detectable levels of free COX5A subunit, but not COX4, under physiological conditions (Figures 3A and 3D).

Most of the subcomplexes that we have identified in probed tissues apparently correspond to known assembly intermediates \cite{15} and/or to subassemblies identified in cultured human cells \cite{14}. Therefore it is unlikely that they represent irrelevant aggregates or parts of labile enzyme with disrupted tertiary interactions.

To rule out possible proteolytic breakdown, the correct size of detected subunits was confirmed on two-dimensional native/de-naturing immunoblots. Taken together, we assume that the subcomplexes identified in the present study correspond to protected rate-limiting steps relevant to the normal assembly pathway (assembly intermediates) that accumulate in mitochondria of patients due to the impaired biogenesis or maintenance of COX.

The \textit{SCO}2 mutations carried by our patients are thought to reduce the efficiency with which the Cu₄ centre of COX2 is formed \cite{11,28}. In the present study, we show that, in \textit{SCO}2-deficient mitochondria, the assembly process is stalled before COX2 associates with the COX1·COX4·COX5A subcomplex. Indeed, all investigated \textit{SCO}2-deficient tissues with severely reduced holoenzyme contained increased levels of COX1-, COX4- and COX5A-containing subcomplexes. The fact that the immunoblots did not reveal accumulation of free COX2 or COX2-containing subcomplex(es) suggests that the lack of Cu₄ centre within COX2 results either in (i) decreased stability of the subunit or (ii) diminished efficiency of its interaction with the COX1·COX4·COX5A subcomplex. However, the latter would require that the stability of Cu₄ lacking free COX2 is low enough, albeit not directly responsible for assembly impairment, to prevent its accumulation in mitochondria of patients. Interestingly, the profile of COX assembly defects observed in \textit{SCO}2 patient tissues closely resembles the situation in cells with inhibited mitochondrial protein synthesis due to doxycycline treatment \cite{15}.
The precise molecular basis of tissue-specific consequences of SCO2 and SURF1 mutations remains unresolved. In addition to different levels of COX holenzyme, variable levels of subcomplexes were found among different tissues, although some of them displayed the same residual level of the holoenzyme (e.g., heart and muscle). This is likely to be attributable to different rates of clearance of partially assembled or unassembled subunits. The tissue-specific pattern of assembly defects only partially overlaps with the expression of particular tissue-specific isoforms of COX subunits, suggesting the involvement of a rather different mechanism. In our patients, the mutant SCO2 protein was almost undetectable in brain and heart with profound COX deficiency, whereas the liver, and particularly fibroblasts, contained small but significant amounts of residual SCO2. However, we find it unlikely that this minor difference could account for the distinct biochemical and clinical involvement of these tissues, unless there is a pronounced difference in ‘spare capacity’ of SCO2 for copper delivery to the CuA centre in these tissues. Therefore we speculate that tissue-specific consequences of SCO2 and SURF1 mutations, in terms of both holoenzyme and subcomplex levels, suggest the existence of tissue-specific functional differences of these proteins that may have evolved to meet different requirements for the regulation of COX biogenesis.

This work was supported by grants from the Grant Agency of Charles University (GAUK 17/2004/C to L.S.) and the Grant Agency of Czech Republic (GACR 303/03/0132 to L.C. and GACR 303/03/0749 to J.H.), by the European Union’s Sixth Framework Programme for Research, Priority 1 ‘Life sciences, genomics and biotechnology for health’ (LSHM-CT-2004-503116 to P.P. and M.T.), and institutional projects (CAG 1M837805002 to J.Z. and MSM0021620806 to H.H. and K.V.). We acknowledge S. Knopova for technical assistance.

REFERENCES
9 Papadopoulou, L. C. and GACR 303/03/0132 to L.C. and GACR 303/03/0749 to J.H.), by the European Union’s Sixth Framework Programme for Research, Priority 1 ‘Life sciences, genomics and biotechnology for health’ (LSHM-CT-2004-503116 to P.P. and M.T.), and institutional projects (CAG 1M837805002 to J.Z. and MSM0021620806 to H.H. and K.V.). We acknowledge S. Knopova for technical assistance.

REFERENCES
9 Papadopoulou, L. C. and GACR 303/03/0132 to L.C. and GACR 303/03/0749 to J.H.), by the European Union’s Sixth Framework Programme for Research, Priority 1 ‘Life sciences, genomics and biotechnology for health’ (LSHM-CT-2004-503116 to P.P. and M.T.), and institutional projects (CAG 1M837805002 to J.Z. and MSM0021620806 to H.H. and K.V.). We acknowledge S. Knopova for technical assistance.

REFERENCES
9 Papadopoulou, L. C. and GACR 303/03/0132 to L.C. and GACR 303/03/0749 to J.H.), by the European Union’s Sixth Framework Programme for Research, Priority 1 ‘Life sciences, genomics and biotechnology for health’ (LSHM-CT-2004-503116 to P.P. and M.T.), and institutional projects (CAG 1M837805002 to J.Z. and MSM0021620806 to H.H. and K.V.). We acknowledge S. Knopova for technical assistance.


Received 16 May 2005/5 August 2005; accepted 8 August 2005
Published as BJ Immediate Publication 8 August 2005, doi:10.1042/BJ20050807

© 2005 Biochemical Society